^
Association details:
| Biomarker: | KIT mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | Sutent (sunitinib) (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor) + bezuclastinib (PLX9486) (c-KIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020
Published date:
11/18/2020
Excerpt:
...results from its PLX9486 + sunitinib Phase 1/2 study in patients with advanced gastrointestinal stromal tumors (GIST...These data suggest that treatment with a combination of PLX9486, a type 1 KIT inhibitor with activity against exon 17 mutations, and sunitinib, a type 2 KIT inhibitor with activity against exon 13 mutations, may provide substantial clinical benefit over treatment with type I or type II inhibitors alone.
